Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
M Zuazo, H Arasanz, A Bocanegra… - EMBO molecular …, 2020 - embopress.org
The search for non‐invasive systemic biomarkers of response to PD‐L1/PD‐1 blockade
immunotherapy is currently a priority in oncoimmunology. In contrast to classical tumor
biomarkers, the identification of clinically useful immunological biomarkers is certainly a
challenge, as anti‐cancer immune responses depend on the coordinated action of many cell
types. Studies on the dynamics of systemic CD 8 T‐cell populations have provided
indications that such biomarkers may have a place in clinical practice. However, the power …
immunotherapy is currently a priority in oncoimmunology. In contrast to classical tumor
biomarkers, the identification of clinically useful immunological biomarkers is certainly a
challenge, as anti‐cancer immune responses depend on the coordinated action of many cell
types. Studies on the dynamics of systemic CD 8 T‐cell populations have provided
indications that such biomarkers may have a place in clinical practice. However, the power …
以上显示的是最相近的搜索结果。 查看全部搜索结果